Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH

Biomarkers in Medicine

Volumn 9, Issue 11, 2015, Pages 1189-1200

  Wang, Yuping ^a   Liu, Zhichao ^a   Zou, Wen ^a   Hong, Huixiao ^a   Fang, Hong ^a   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

biomarker; drug induced liver disease; fibrosis; miRNA; nonalcoholic fatty liver disease; steatohepatitis; steatosis

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 103; MICRORNA 122; MICRORNA 125 5P; MICRORNA 1290; MICRORNA 146B; MICRORNA 150; MICRORNA 16; MICRORNA 17; MICRORNA 181D; MICRORNA 182; MICRORNA 183; MICRORNA 197; MICRORNA 199A 5P; MICRORNA 19A; MICRORNA 21; MICRORNA 219 5P; MICRORNA 219A; MICRORNA 224; MICRORNA 27B 3P; MICRORNA 31; MICRORNA 33A; MICRORNA 34A; MICRORNA 375; MICRORNA 378I; MICRORNA 590; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

DRUG INDUCED DISEASE; FATTY LIVER; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; LIVER FIBROSIS; LIVER INJURY; MOLECULAR INTERACTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; RNA TRANSCRIPTION; ANIMAL; DISEASE COURSE; GENETICS; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ANIMALS; BIOMARKERS; DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84947779176     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.70     Document Type: Review

References (72)

1. Ahmed M. Non-alcoholic fatty liver disease in 2015. World J. Hepatol. 7(11), 1450-1459 (2015).
2. Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int. J. Mol. Sci. 16(3), 5161-5179 (2015).
3. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 136(4), 642-655 (2009).
4. Londin E, Loher P, Telonis AG et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate-and tissue-specific microRNAs. 112(10), E1106-E1115 (2015).
5. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol. 14(8), 475-488 (2013).
6. Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions-beyond repression of gene expression. Nat. Rev. Genet. 15(9), 599-612 (2014).
7. Kong YW, Ferland-Mccollough D, Jackson TJ, Bushell M. MicroRNAs in cancer management. Lancet Oncol. 13(6), e249-258 (2012).
8. Kamal MA, Mushtaq G, Greig NH. Current update on synopsis of miRNA dysregulation in neurological disorders. CNS Neurol. Dis. Drug Target. 14(4), 492-501 (2015).
9. Oliveira-Carvalho V, Da Silva MM, Guimaraes GV, Bacal F, Bocchi EA. MicroRNAs: new players in heart failure. Mol. Biol. Rep. 40(3), 2663-2670 (2013).
10. Lamontagne J, Steel LF, Bouchard MJ. Hepatitis B virus and microRNAs: complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. World J. Gastroenterol. 21(24), 7375-7399 (2015).
11. Baldeon RL, Weigelt K, De Wit H et al. Type 2 diabetes monocyte microRNA and mRNA expression: dyslipidemia associates with increased differentiation-related genes but not inflammatory activation. PLoS ONE 10(6), e0129421 (2015).
12. Zhou B, Li Z, Yang H, He N. Extracellular miRNAs: origin, function and biomarkers in hepatic diseases. J. Biomed. Nanotechnol. 10(10), 2865-2890 (2014).
13. Krauskopf J, Caiment F, Claessen SM et al. Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol. Sci. 143(2), 268-276 (2015).
14. Ayyadurai S, Charania MA, Xiao B, Viennois E, Zhang Y, Merlin D. Colonic miRNA expression/secretion, regulated by intestinal epithelial pept1, plays an important role in cell-to-cell communication during colitis. PLoS ONE 9(2), e87614 (2014).
15. Kogure T, Costinean S, Yan I, Braconi C, Croce C, Patel T. Hepatic miR-29AB1 expression modulates chronic hepatic injury. J. Cell. Mol. Med. 16(11), 2647-2654 (2012).
16. Scherr M, Elder A, Battmer K, Barzan D, Bomken S. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. 28(3), 554-565 (2014).
17. Bostjancic E, Glavac D. Mirnome in myocardial infarction: future directions and perspective. World. J. Cardiol. 6(9), 939-958 (2014).
18. Chen L, Hou J, Ye L et al. MicroRNA-143 regulates adipogenesis by modulating the MAP2K5-ERK5 signaling. Sci. Rep. 4, 3819 (2014).
19. Christian P, Su Q. MicroRNA regulation of mitochondrial and er stress signaling pathways: implications for lipoprotein metabolism in metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 307(9), E729-737 (2014).
20. Mattis AN, Song G, Hitchner K et al. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatol. (Baltimore, MD) 61(1), 141-152 (2015).
21. Chakraborty C, Doss CG, Bandyopadhyay S, Agoramoorthy G. Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in Type-2 diabetes. Wiley Interdiscip. Rev. RNA 5(5), 697-712 (2014).
22. Panera N, Gnani D, Crudele A, Ceccarelli S, Nobili V, Alisi A. MicroRNAs as controlled systems and controllers in nonalcoholic fatty liver disease. World J. Gastroenterol. 20(41), 15079-15086 (2014).
23. Itoh M, Kato H, Suganami T et al. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS ONE 8(12), e82163 (2013).
24. Li Y, Kowdley KV. MicroRNAs in common human diseases. Genom. Proteom. Bioinform. 10(5), 246-253 (2012).
25. Sanyal AJ, Brunt EM, Kleiner DE et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatol. (Baltimore, MD) 54(1), 344-353 (2011).
26. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10(12), 1342-1359. e1342 (2012).
27. Gerhard GS, Distefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J. Hepatol. 7(2), 226-234 (2015).
28. Chen Y, Verfaillie CM. MicroRNAs: the fine modulators of liver development and function. Liver Int. 34(7), 976-990 (2014).
29. Price NL, Ramirez CM, Fernandez-Hernando C. Relevance of microRNA in metabolic diseases. Crit. Rev. Clin. Lab. Sci. 51(6), 305-320 (2014).
30. Williams JA, Manley S, Ding WX. New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases. World J. Gastroenterol. 20(36), 12908-12933 (2014).
31. Singaravelu R, Chen R, Lyn RK et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatol. (Baltimore, MD) 59(1), 98-108 (2014).
32. Vickers KC, Sethupathy P, Baran-Gale J, Remaley AT. Complexity of microRNA function and the role of isomirs in lipid homeostasis. J. Lipid Res. 54(5), 1182-1191 (2013).
33. Li T, Francl JM, Boehme S, Chiang JY. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7alpha-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice. Hepatol. (Baltimore, MD) 58(3), 1111-1121 (2013).
34. Horie T, Nishino T, Baba O et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat. Comm. 4, 2883 (2013).
35. Goedeke L, Vales-Lara FM, Fenstermaker M et al. A regulatory role for microRNA 33∗in controlling lipid metabolism gene expression. Mol. Cell. Biol. 33(11), 2339-2352 (2013).
36. Gharipour M, Sadeghi M. Pivotal role of microRNA-33 in metabolic syndrome: a systematic review. ARYA Atheroscler. 9(6), 372-376 (2013).
37. Ramirez CM, Goedeke L, Rotllan N et al. MicroRNA regulates glucose metabolism. Mol. Cell. Biol. 33(15), 2891-2902 (2013).
38. Cirera-Salinas D, Pauta M, Allen RM et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell Cycle 11(5), 922-933 (2012).
39. Lodhi IJ, Semenkovich CF. Peroxisomes: a nexus for lipid metabolism and cellular signaling. Cell Metab. 19(3), 380-392 (2014).
40. Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr. J. 13, 17 (2014).
41. Song K, Han C, Zhang J et al. Epigenetic regulation of microRNA-122 by peroxisome proliferator activated receptorgamma and hepatitis B virus x protein in hepatocellular carcinoma cells. Hepatology 58(5), 1681-1692 (2013).
42. Peyrou M, Ramadori P, Bourgoin L, Foti M. Ppars in liver diseases and cancer: epigenetic regulation by microRNAs. PPAR Res. 2012 757803 (2012).
43. Escalona-Nandez I, Guerrero-Escalera D, Estanes-Hernandez A, Ortiz-Ortega V, Tovar AR, Perez-Monter C. The activation of peroxisome proliferator-activated receptor gamma is regulated by Kruppel-like transcription factors 6 & under steatotic conditions. Biochem. Biophys. Res. Comm. 458(4), 751-756 (2015).
44. Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World. J. Hepatol. 6(8), 570-579 (2014).
45. Lima-Cabello E, Garcia-Mediavilla M, Miquilena-Colina M et al. Enhanced expression of pro-inflammatory mediators and liver x-receptor-regulated lipogenic genes in nonalcoholic fatty liver disease and hepatitis c. Clin. Sci. 120, 239-250 (2011).
46. Yang T, Li X, Zhu W et al. Alteration of antioxidant enzymes and associated genes induced by grape seed extracts in the primary muscle cells of goats in vitro. PLoS ONE 9(9), e107670 (2014).
47. Lehmann M, Pirinen E, Mirsaidi A et al. ARTD1-induced poly-ADP-ribose formation enhances ppargamma ligand binding and co-factor exchange. Nucl. Acids Res. 43(1), 129-142 (2015).
48. Gao Y, Shen W, Lu B, Zhang Q, Hu Y, Chen Y. Upregulation of hepatic VLDLR via PPARalpha is required for the triglyceride-lowering effect of fenofibrate. J. Lipid Res. 55(8), 1622-1633 (2014).
49. Roberts LD, Bostrom P, O'Sullivan JF et al. Betaaminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 19(1), 96-108 (2014).
50. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of pparalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62(3), 720-733 (2015).
51. Kurtz M, Capobianco E, Careaga V et al. Peroxisome proliferator-activated receptor ligands regulate lipid content, metabolism, and composition in fetal lungs of diabetic rats. J. Endocrinol. 220(3), 345-359 (2014).
52. Albert JS, Yerges-Armstrong LM, Horenstein RB et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N. Engl. J. Med. 370(24), 2307-2315 (2014).
53. Zhou J, Wang KC, Wu W et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc. Natl Acad. Sci. USA 108(25), 10355-10360 (2011).
54. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 20(42), 15539-15548 (2014).
55. Rius B, Titos E, Moran-Salvador E et al. Resolvin d1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB J. 28(2), 836-848 (2014).
56. Chen YP, Jin X, Xiang Z, Chen SH, Li YM. Circulating microRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int. 33(8), 1257-1265 (2013).
57. Leti F, Malenica I, Doshi M et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Translat. Res. (2015).
58. Csak T, Bala S, Lippai D et al. MicroRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 35(2), 532-541 (2015).
59. Enache LS, Enache EL, Ramiere C et al. Circulating RNA molecules as biomarkers in liver disease. Int. J. Mol. Sci. 15(10), 17644-17666 (2014).
60. Elpek GO. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. World J. Gastroenterol. 20(23), 7260-7276 (2014).
61. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14(3), 181-194 (2014).
62. Lee SH, Do SI, Kim HS. Hyperoxia accelerates progression of hepatic fibrosis by up-regulation of transforming growth factor-beta expression. World J. Gastroenterol. 20(11), 3011-3017 (2014).
63. Tan J, Tong BD, Wu YJ, Xiong W. MicroRNA-29 mediates TGFbeta1-induced extracellular matrix synthesis by targeting wnt/beta-catenin pathway in human orbital fibroblasts. Int. J. Clin. Exp. Pathol. 7(11), 7571-7577 (2014).
64. Kwiecinski M, Elfimova N, Noetel A et al. Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab. Invest. 92(7), 978-987 (2012).
65. Wang Y, Chen T, Tong W. MiRNAs and their application in drug-induced liver injury. Biomark. Med. 8(2), 161-172 (2014).
66. Jaeschke H. Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury? Toxicol. Sci. 97(1), 1-3 (2007).
67. Alizadeh E, Akbarzadeh A, Eslaminejad MB et al. Up regulation of liver-enriched transcription factors HNF4a and HNF6 and liver-specific microRNA (miR-122) by inhibition of Let-7b in mesenchymal stem cells. Chem. Biol. Drug Design 85(3), 268-279 (2015).
68. Klaassen CD, Lu H, Cui JY. Epigenetic regulation of drug processing genes. Toxicol. Mech. Method. 21(4), 312-324 (2011).
69. Sawant DV, Yao W, Wright Z et al. Serum microRNA-21 as a biomarker for allergic inflammatory disease in children. MicroRNA 4(1), 36-40 (2015).
70. Wu K, Li L, Li S. Circulating microRNA-21 as a biomarker for the detection of various carcinomas: an updated metaanalysis based on 36 studies. Tumour Biol. 36(3), 1973-1981 (2015).
71. Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin. Chem. 61(1), 56-63 (2015).
72. Tang G, Shen X, Lv K, Wu Y, Bi J, Shen Q. Different normalization strategies might cause inconsistent variation in circulating microRNAs in patients with hepatocellular carcinoma. Med. Sci. Monitor. 21, 617-624 (2015).